Topic

North Carolina

A collection of 251 issues

How to Get Procysbi (Cysteamine Bitartrate DR) Covered by Blue Cross Blue Shield in North Carolina: Complete PA Guide with Appeals Timeline

Answer Box: Getting Procysbi Covered by BCBS North Carolina Procysbi (cysteamine bitartrate DR) requires prior authorization from Blue Cross Blue Shield of North Carolina, with step therapy requirements typically mandating a trial of immediate-release cysteamine first. Your fastest path to approval: 1. Gather documentation: Confirmed nephropathic cystinosis diagnosis (ICD-10: E72.
7 min read

Do You Qualify for Hetlioz (Tasimelteon) Coverage by Cigna in North Carolina? Decision Tree & Next Steps

Answer Box: Qualifying for Hetlioz (Tasimelteon) Coverage You likely qualify for Cigna coverage of Hetlioz (tasimelteon) in North Carolina if you have: * Confirmed Non-24-Hour Sleep-Wake Disorder or Smith-Magenis Syndrome diagnosis * Sleep specialist evaluation with 14+ days of sleep logs/actigraphy * Documentation of failed alternative treatments (if step therapy applies) Fastest
6 min read

Myths vs. Facts: Getting Tremfya (Guselkumab) Covered by Humana in North Carolina

Answer Box: Getting Tremfya Covered by Humana in North Carolina Eligibility: Moderate-to-severe plaque psoriasis with PASI ≥10 or equivalent severity, failed conventional systemic therapy (methotrexate, cyclosporine), and negative TB screening within 12 months. Fastest path: Work with a dermatologist to submit prior authorization with complete documentation: diagnosis severity scores, prior
5 min read

How to Get Pombiliti (cipaglucosidase alfa-atga) Covered by Aetna CVS Health in North Carolina: Timeline, Appeals & Documentation Guide

Answer Box: Getting Pombiliti Covered by Aetna CVS Health in North Carolina Pombiliti (cipaglucosidase alfa-atga) requires prior authorization from Aetna CVS Health with strict documentation requirements. The fastest path to approval: (1) Confirm diagnosis of late-onset Pompe disease with enzyme/genetic testing, (2) Document inadequate response to prior ERT therapy,
5 min read